An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup.

J Clin Invest 2019 Jan 26;129(1):169-181. Epub 2018 Nov 26.

Department of Medicine, UCSF, San Francisco, California, USA.

Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous smoking-related disease characterized by airway obstruction and inflammation. This inflammation may persist even after smoking cessation and responds variably to corticosteroids. Personalizing treatment to biologically similar "molecular phenotypes" may improve therapeutic efficacy in COPD. IL-17A is involved in neutrophilic inflammation and corticosteroid resistance, and thus may be particularly important in a COPD molecular phenotype.

Methods: We generated a gene expression signature of IL-17A response in bronchial airway epithelial brushings from smokers with and without COPD (n = 238), and validated it using data from 2 randomized trials of IL-17 blockade in psoriasis. This IL-17 signature was related to clinical and pathologic characteristics in 2 additional human studies of COPD: (a) SPIROMICS (n = 47), which included former and current smokers with COPD, and (b) GLUCOLD (n = 79), in which COPD participants were randomized to placebo or corticosteroids.

Results: The IL-17 signature was associated with an inflammatory profile characteristic of an IL-17 response, including increased airway neutrophils and macrophages. In SPIROMICS the signature was associated with increased airway obstruction and functional small airways disease on quantitative chest CT. In GLUCOLD the signature was associated with decreased response to corticosteroids, irrespective of airway eosinophilic or type 2 inflammation.

Conclusion: These data suggest that a gene signature of IL-17 airway epithelial response distinguishes a biologically, radiographically, and clinically distinct COPD subgroup that may benefit from personalized therapy.

Trial Registration: ClinicalTrials.gov NCT01969344.

Funding: Primary support from the NIH, grants K23HL123778, K12HL11999, U19AI077439, DK072517, U01HL137880, K24HL137013 and R01HL121774 and contracts HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C and HHSN268200900020C.

Download full-text PDF

Source
http://www.jci.org/articles/view/121087
Publisher Site
http://dx.doi.org/10.1172/JCI121087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307967PMC
January 2019
44 Reads

Publication Analysis

Top Keywords

airway epithelial
12
signature associated
12
copd
9
airway obstruction
8
increased airway
8
smokers copd
8
il-17a response
8
il-17 signature
8
signature
7
airway
7
response
5
il-17
5
corticosteroids irrespective
4
238 validated
4
irrespective airway
4
airway eosinophilic
4
validated data
4
data randomized
4
response corticosteroids
4
blockade psoriasis
4

References

(Supplied by CrossRef)

Similar Publications